RankAlpha logo
Back to Rankings

HROW

HarrowD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
The primary-source bull case is that Harrow now has a larger ophthalmic commercial platform, 2025 product-sales growth, year-end cash of $72.9 million, and fresh March 2026 financing earmarked partly for launches and development, which could support a stronger 2026-2027 revenue base if mid-2026 launches land well.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -0.8.
What can break
Forward visibility is still modest because the current packet lacks fresh trusted-news or analyst-revision confirmation after the annual filing and March financing event.
Momentum
9
Value
50
Sentiment
82
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $43.00 · Bull $58.00 · Bear $30.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-05 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $69.13
Why
Momentum9 · Δ7d +2.2
Value50 · Δ7d +0.1
Sentiment82 · Δ7d -0.8
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
9
34% active weight
Current posture
7d trendFlat
Δ7d
+2.2
Δ21d
-21.4
Value
50
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
82
33% active weight
Current posture
7d trendFlat
Δ7d
-0.8
Δ21d
+22.3
Why this grade

Composite grade D. Momentum 8.6 / Value 49.8 / Sentiment 81.7

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$1.27B
Beta
0.07
Shares Out
37.04M
P/E (TTM) · Derived
-245.6
P/S (TTM)
8.12
P/FCF (TTM) · Derived
-62.26
Rev YoY
+45.4%
EPS YoY
+122.2%
Gross Margin
+74.6%
Op Margin
+8.0%
Net Debt
$172.29M
Current Ratio
2.72
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology